BRAF inhibitors (BRAFis) have prolonged the survival of patients with advanced BRAF-mutated melanoma. Recent reports suggest that BRAFis not only inhibit growth signal of melanoma cells but also play an immunomodulatory role by affecting tumor-infiltrating lymphocytes and the expression of programmed cell death ligand 1 (PD-L1) and major histocompatibility complex (MHC) in melanoma cells.1,2 Herein, we report a case of melanoma, which was initially resistant to nivolumab treatment, but showed a remarkable response to rechallenge with nivolumab after vemurafenib therapy.
Kato J, Hida T, Kamiya T, et al. Rechallenge With Nivolumab After Vemurafenib Treatment of Initially Nivolumab-Resistant Advanced Melanoma. JAMA Dermatol. 2018;154(5):621–622. doi:10.1001/jamadermatol.2017.6400
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: